Medtec is a specialized exhibition dedicated to delivering solutions for medical device R&D and manufacturing. Its 20th edition will take place from September 1-3, 2026, and will relocate to a new venue: SNIEC (Pudong) N1-N4.
Visitor Badge can be applied in March 2026, the pre-registration is for free while the ticket will cost ￥100 onsite from September 1 to 3.
Background:
Currently, China’s medical aesthetics market is experiencing a high-growth blue ocean phase, with the market size projected to reach RMB 348.9 billion by 2026, sustaining a compound annual growth rate (CAGR) of 9.1%. The penetration rate is expected to rise to 7.2%, as the industry shifts from unregulated expansion to a phase characterized by compliance and professionalism. At the policy level, comprehensive regulation and supportive guidance go hand in hand. The State Council’s Order No. 828 strengthens oversight of medical aesthetic devices, while financial and tax standardization policies drive industry consolidation. Concurrently, the encouragement of new material R&D and clinical transformation compels the industry to realign with its medical origins. By 2026, the medical aesthetics sector will usher in the era of clinical applications in tissue engineering, with recombinant Type III collagen taking center stage. Alongside regenerative materials (PCL/PLLA) and cross-linked hyaluronic acid composites, it will constitute a “one core, two wings” framework. However, the industry predominantly focuses on aesthetic applications, neglecting the vast potential of these regenerative materials in treating serious medical conditions within the tissue engineering domain. Given this context, the specialized medical aesthetics forum currently centers on the theme of “New Material Development and Clinical Applications.” It goes beyond mere industry trend discussions, focusing instead on innovative materials in medical aesthetics and their critical application scenarios—serious medical treatments. The forum established a platform for collaboration among industry, academia, research, and clinical practice, aiming to drive breakthroughs in material technology and clinical implementation, thereby fostering high-quality development in the sector.
Participants:
- Medical device manufacturers: heads of the departments of R&D, design, and technology, as well as project/company leaders
- Medical beauty materials and equipment suppliers and service providers
- Doctors, and research institutes, etc.
Agenda:
| Time | Topic |
| 9:50-10:00 | Moderator Remarks |
| 10:00-10:30 | Breakthroughs in Recombinant Collagen R&D and Technological Advancements |
| 10:30-11:00 | Industrialization Challenges and Breakthroughs in Hydroxyapatite Technology |
| 11:00-11:30 | Research and Application of Novel Synthetic Regenerative Materials |
| 11:30-12:00 | Progress in Polylactic Acid Materials |
| 12:00-12:10 | Conference Close |
Background:
Currently, China has entered a deeply moderate aging society, with the population aged 60 and above surpassing the 300 million mark. Concurrently, the prevention and control of chronic diseases face increasingly severe challenges, with approximately 245 million hypertension patients and 140 million diabetes patients nationwide. However, less than 20% of this extensive chronic disease population effectively manages their conditions outside hospital environments. Home-based and wearable medical devices have emerged as pivotal tools to bridge the gap in out-of-hospital chronic disease management, driving a transformation from “passive treatment” to “active prevention.” The accuracy of data and clinical effectiveness of these devices directly influence chronic disease diagnosis, treatment, and health outcomes, rendering them a central focus and urgent demand for industry advancement.
However, the industry still faces core technological bottlenecks, such as insufficient accuracy in non-invasive blood glucose monitoring sensors, challenges in clinical validation of monitoring data, and algorithms failing to meet clinical standards in sensitivity and specificity. Meanwhile, regulatory oversight is intensifying. The National Medical Products Administration (NMPA) consistently elevates classification definitions and certification criteria for medical-grade wearable devices. The industry’s chaotic trend of “prioritizing consumer appeal over medical efficacy” is gradually being rectified. Enterprises equipped with core technologies and compliance capabilities are poised to enter a phase of developmental dividends.
This forum will focus on breakthroughs in core technologies for home and wearable medical-grade devices, optimization of clinical adaptation, and implementation in chronic disease management scenarios. It aims to facilitate the industry’s transition from “hardware sales” to “digital health management platforms,” providing more efficient, precise, and convenient medical technology support for chronic disease prevention and control.
Participants:
- Home and wearable medical device manufacturers: R&D, design, and technology departments, as well as project/enterprise leaders
- Related equipment suppliers and service providers
- Doctors, universities, research institutions, etc.
Agenda:
| Time | Topic |
| 13:50-14:00 | Moderator Remarks |
| 14:00-14:30 | The Role of Wearable Medical Devices in Chronic Disease Management |
| 14:30-15:00 | New Sensors and Artificial Intelligence: Ushering in the Smart Era of Non-Invasive Blood Glucose Monitoring |
| 15:00-15:30 | 12-Lead Ultra-Long-Range Flexible ECG Sensing Technology — Ushering in a New Era of Full-Cycle Management for Cardiovascular Chronic Diseases |
| 15:30-16:00 | Wrist & Fingertip Non-Invasive Blood Glucose Monitoring and Construction of a Full-Cycle Closed-Loop Chronic Disease Management System for Home Care |
| 16:00-16:10 | Conference Close |